Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
NCT06644768 · View on ClinicalTrials.gov ↗
Study Summary
This study will compare Valemetostat Tosylate Plus Pembrolizumab vs Pembrolizumab Alone in First-line NSCLC Without Actionable Genomic Alterations
Conditions Studied
Interventions
- DRUG pembrolizumab
- DRUG valemetostat tosylate
Study Locations (20)
Other
- Hospital Italiano de Buenos Aires — Buenos Aires
- Instituto Alexander Fleming — Buenos Aires
- Sanatorio Allende — Córdoba
- Fundacion Ars Medica — N Salvador de Jujuy
- Centro de Investigacion Pergamino Sa — Pergamino
- Instituto Medico de La Fundacion Estudios Clinicos — Rosario
- Clinica Viedma S.A. — Viedma
- Centro de Pesquisas Clinica Reichow — Blumenau
California
- University of California San Diego (Ucsd)-Moores Cancer Center — La Jolla
- California Research Institute — Los Angeles
- Valkyrie Clinical Trials — Los Angeles
Florida
- Mayo Clinic Hospital — Jacksonville
- BRCR Global — Plantation
Kentucky
- University of Kentucky Medical Center — Lexington
- Pikeville Medical Center — Pikeville
New York
- Columbia University Irving Medical Center — New York
- Montefiore Medical Center — The Bronx
Minnesota
- Mayo Clinic - Rochester — Rochester
Pennsylvania
- Thomas Jefferson University, Sidney Kimmel Cancer Center — Philadelphia
Virginia
- Virginia Cancer Specialist — Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2024-10-30 |
| Est. Completion | 2030-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06644768
The ClinicalTrials.gov registry entry for NCT06644768 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 137 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 157 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions — of which pembrolizumab is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06644768 reports 20 study locations spanning 8 distinct geographic areas — top geographies include Other, California, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06644768 about?
NCT06644768 is a clinical study titled "A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations". This study will compare Valemetostat Tosylate Plus Pembrolizumab vs Pembrolizumab Alone in First-line NSCLC Without Actionable Genomic Alterations
What is the current status of trial NCT06644768?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 137 participants. The study started on 2024-10-30. Estimated completion is 2030-04-30.
What conditions does trial NCT06644768 study?
This clinical trial studies the following conditions: Lung Cancer, Non-small Cell Lung Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06644768?
The interventions under investigation include: pembrolizumab (DRUG), valemetostat tosylate (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06644768?
This trial is sponsored by Daiichi Sankyo, which has 157 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06644768 being conducted?
This trial has 20 study locations across California, Florida, Kentucky, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.